<DOC>
	<DOCNO>NCT02210559</DOCNO>
	<brief_summary>This Phase 1/2 trial evaluate safety , tolerability efficacy FG-3019 administer gemcitabine Nab-paclitaxel treatment locally advance , unresectable pancreatic cancer .</brief_summary>
	<brief_title>A Phase 1/2 Trial Gemcitabine Plus Nab-paclitaxel With Without FG-3019 Neoadjuvant Chemotherapy Locally Advanced , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Each subject may receive six cycle treatment ( treatment cycle 28 day ) . Tumor tissue collect resection biomarker analysis . EUS core tumor biopsy collect pre/post treatment participate center . Tumor response evaluate change CT scan , FDG-PET , CA 19-9 , NCCN® guideline . Subjects complete 6 cycle treatment evaluate surgical exploration possible R0 resection . Subjects undergo surgery evaluate surgical complication additional 30 day follow discharge surgery . All subject follow safety 28 day follow last dose study drug . Blood sample collect periodically assessment pharmacokinetics ( PK ) pharmacodynamics ( PD ) . All subject , include discontinue study treatment period without evidence disease progression , follow least 28 week post End Treatment disease progression , survival , follow-on treatment pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Male nonpregnant , nonlactating female Histologically proven diagnosis pancreatic ductal adenocarcinoma ( PDAC ) Radiographic pathologic stag consistent pancreatic cancer , locally advanced , unresectable ( per NCCN criterion ) Laparoscopic confirmation PDAC locally advance . Biliary stent permit Measurable disease define RECIST 1.1 ECOG performance status 0 1 Adequate liver , bone marrow renal function Agree use contraception per protocol Less Grade 2 preexist peripheral neuropathy Key Prior chemotherapy radiation pancreatic cancer Solid tumor contact SMA &gt; 180° Previous ( within past 5 year ) concurrent malignancy diagnosis ( expect nonmelanoma skin cancer situ carcinoma cervix ) Major surgery within 4 week prior Day 1 study History allergy hypersensitivity human , humanize chimeric monoclonal antibody Exposure another investigational drug within 42 day first dose visit , 5 halflives study product ( whichever longer ) Uncontrolled intercurrent illness Any medical condition , opinion Investigator , may pose safety risk subject trial , may confound assessment safety efficacy , may interfere study participation . Current abuse alcohol drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>locally</keyword>
	<keyword>advanced</keyword>
	<keyword>pancreatic</keyword>
	<keyword>cancer</keyword>
	<keyword>unresectable</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>